Tyrell J. Rivers, Ph.D., has served as a member of ADC Therapeutics' board of directors since June 2018. He is a Vice President within AstraZeneca's Corporate Development & Ventures group, where he has been since 2014, and from 2009 to 2014 was at MedImmune Ventures specializing in biotechnology investing. He also serves on the board of Cellectis. Dr. Rivers holds a B.S. in chemical engineering from the Massachusetts Institute of Technology, an M.S. in engineering and a Ph.D. in chemical engineering from the University of Texas at Austin, and an M.B.A. from New York University's Stern School of Business.